Ankleshwar (Gujarat)-based custom synthesis manufacturer of pharmaceutical intermediates and speciality/fine chemicals, built on complex halogenation and reduction chemistry.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 9 | 10 | 12 | 13 | 13 | 13 | 13 | 13 |
| Reserves | 33 | 40 | 50 | 75 | 109 | 132 | 141 | 150 |
| Borrowings | 2 | 0 | 0 | 33 | 36 | 38 | 38 | 31 |
| Other Liabilities | 8 | 10 | 15 | 18 | 12 | 8 | 13 | 14 |
| Total Liabilities | 52 | 61 | 77 | 138 | 171 | 192 | 204 | 208 |
| AssetsFixed Assets | 16 | 19 | 27 | 58 | 81 | 95 | 105 | 105 |
| CWIP | 0 | 2 | 3 | 15 | 17 | 9 | 9 | 12 |
| Investments | 7 | 3 | 0 | 0 | 5 | 18 | 19 | 13 |
| Other Assets | 29 | 37 | 47 | 64 | 69 | 70 | 71 | 78 |
| Total Assets | 52 | 61 | 77 | 138 | 171 | 192 | 204 | 208 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | -5 | 4 | 3 | 13 | 17 | 30 | 31 | 24 |
| Cash from Investing | 0 | -3 | -1 | -12 | -51 | -33 | -35 | -10 |
| Cash from Financing | 0 | 0 | -1 | -1 | 39 | 10 | -1 | -12 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | -5 | 4 | 3 | -2 | -32 | -1 | 7 | 7 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (35.0×) and current (50.8×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At -0.1% growth and a 35× exit, ₹703 only delivers your return if you pay ₹198. The price is currently baking in 26% growth.
EPS grows -0.1%/yr for 5 years, then fades to 6% over 2, exits at 35×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | -0.1% | 13.83 |
| FY28 | -0.1% | 13.81 |
| FY29 | -0.1% | 13.80 |
| FY30 | -0.1% | 13.78 |
| FY31 | -0.1% | 13.77 |
| FY32 | 2.9% ·fade | 14.18 |
| FY33 | 6.0% ·fade | 15.03 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.